Literature DB >> 30521867

Evaluation of the automated BD Phoenix CPO Detect panel in combination with the β-CARBA assay for detection and classification of carbapenemase-producing Enterobacterales.

Michaela Simon1, Soeren Gatermann2, Yvonne Pfeifer3, Udo Reischl4, André Gessner4, Jonathan Jantsch4.   

Abstract

Recently, the CPO Detect panel for the detection of carbapenemase-producing, Gram-negative bacteria was introduced for the Phoenix semi-automated antimicrobial susceptibility testing system. The CPO Detect assay aims to detect carbapenemase activity (P/N test) and to type carbapenemase producers according to the Ambler classification (Ambler test). The P/N test-based detection of carbapenemase producers was 100% sensitive and 55.3% specific in the assessment of 57 carbapenemase-producing and 38 non-carbapenemase-producing Enterobacterales. False-positive test isolates in the P/N test arose from carbapenemase-non-producing, but carbapenem-non-susceptible isolates. In contrast, using the Ambler test-based approach for carbapenemase detection resulted in a specificity of 100% and a sensitivity of 79%. In order to improve the overall performance, we established an algorithm that additionally included the colorimetric β-CARBA assay as downstream test for P/N test-positive isolates, which remained un-typed in the Ambler test. This algorithm displayed an overall sensitivity and specificity of 98.3% and 100%, respectively. Our data demonstrate that the combination of the CPO Detect assay with the β-CARBA test allows for rapid detection and classification of carbapenemase-producing Enterobacterales.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ambler classification; Carbapenem resistance; Carbapenemase detection; Phenotypic colorimetric test

Mesh:

Substances:

Year:  2018        PMID: 30521867     DOI: 10.1016/j.mimet.2018.11.024

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  3 in total

1.  Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales.

Authors:  Jingjia Zhang; Peiyao Jia; Ying Zhu; Ge Zhang; Yingchun Xu; Qiwen Yang
Journal:  Front Med (Lausanne)       Date:  2021-04-14

2.  Evaluation of the BD Phoenix CPO detect panel for prediction of Ambler class carbapenemases.

Authors:  Daniel Jonas; Sandra Reuter; Sarah Klassen; Sabine Weber; Marion Buck; Tommaso Giani; Gian Maria Rossolini; Hajo Grundmann
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

3.  Performance Evaluation of Diagnostic Assays for Detection and Classification of Carbapenemase-Producing Organisms.

Authors:  Anru Zhang; Xiaojuan Wang; Xinyue Liang; Chaoe Zhou; Qi Wang; Jiangang Zhang; Hui Wang
Journal:  Antibiotics (Basel)       Date:  2021-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.